natgillin/translations-raw huggingface dataset:
The following clinical safety features (hepatotoxicity, hyperlipidaemia, bleeding events, rash) were seen at higher frequency among tipranavir with ritonavir treated patients when compared with the comparator arm treated patients in the RESIST trials, or have been observed with tipranavir with ritonavir administration. 
Sljedeća obilježja kliničke sigurnosti (hepatotoksičnost, hiperlipidemija, epizode krvarenja, osip) su primijećena s većom učestalošću među bolesnicima liječenim tipranavirom s ritonavirom u usporedbi s bolesnicima u kontrolnoj skupini u ispitivanjima RESIST, ili su primijećena u primjeni tipranavira s ritonavirom.
Aptivus contains macrogolglycerol ricinoleate which may cause stomach upset and diarrhoea. 
Aptivus sadrži makrogolglicerol ricinoleat koji može uzrokovati želučane tegobe i proljev.
(N=740) versus +4 cells/mm 
3 za ispitivanu skupinu (N=740) i +4 stanice/mm
In the case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant Summary of Product Characteristics for these medicinal products. 
U slučaju istodobnog antivirusnog liječenja hepatitisa B ili C, valja konzultirati Sažetak opisa svojstava lijeka za svaki korišteni lijek za hepatitis.
In addition the majority of participants had mutations associated with both NRTI and NNRTI resistance. 
Nadalje, većina bolesnika imala je viruse s mutacijama povezanim s otpornošću i na NRTI i NNRTI.
In use storage: 60 days (below 25°C), after first opening of the bottle. 
Čuvanje tijekom primjene: 60 dana (ispod 25°C), nakon prvog otvaranja boce.
Aptivus oral solution should be taken with food. 
Aptivus oralna otopina se mora uzeti s hranom.
Herbal preparations containing St John's wort (Hypericum perforatum) due to the risk of decreased plasma concentrations and reduced clinical effects of tipranavir (see section 4.5). 
Biljni pripravci koji sadrže gospinu travu (Hypericum perforatum) zbog rizika od smanjenih koncentracija u plazmi i smanjenih kliničkih učinaka tipranavira (vidjeti dio 4.5).
Anti-infectives 
Antiinfektivni lijekovi
Since tipranavir is highly protein bound, dialysis is unlikely to be beneficial in significant removal of this medicine. 
S obzirom da se tipranavir uvelike veže na proteine plazme, dijaliza vjerojatno neće pospješiti uklanjanje tipranavira.
First-dose tipranavir/r Digoxin Cmax ↔ Digoxin AUC ↔ 
Prva doza tipranavira/r Digoksin Cmax ↔ Digoksin AUC ↔
A reduced virological response was observed in patients with viral strains harbouring two or more mutations at HIV protease codons 33, 82, 84 or 90, and not receiving new enfuvirtide. 
Smanjena virološka reakcija primijećena je u bolesnika s virusnim sojevima s dvije ili više mutacija u HIV proteaznim kodonima 33, 82, 84 ili 90, koji ne primaju „novi“ enfuvirtid.
These active substances include antiarrhythmics (such as amiodarone, bepridil, quinidine), antihistamines (such as astemizole, terfenadine), ergot derivatives (such as dihydroergotamine, ergonovine, ergotamine, methylergonovine), gastrointestinal motility agents (such as cisapride), antipsychotics (such as pimozide, sertindole, quetiapine, lurasidone), sedatives/hypnotics (such as orally administered midazolam and triazolam) and HMG-CoA reductase inhibitors (such as simvastatin and lovastatin) (see section 4.5). 
Ove djelatne tvari uključuju antiaritmike (kao što su amiodaron, bepridil, kinidin), antihistaminike (kao što su astemizol, terfenadin), derivate ergota (kao što su dihidroergotamin, ergonovin, ergotamin, metilergonovin), lijekove za gastrointestinalnu pokretljivost (kao što je cisaprid), antipsihotike (kao što su pimozid, sertindol, kvetiapin, lurasidon), sedative/hipnotike (kao što su oralni midazolam i triazolam) te pri primjeni inhibitora HMG-CoA reduktaze (kao što su simvastatin i lovastatin) (vidjeti dio 4.5).
Patients were required to have a baseline HIV-1 RNA concentration of at least 1500 copies/ml, were stratified by age (2 to < 6 years, 6 to < 12 years and 12 to 18 years) and randomized to receive one of two tipranavir with ritonavir dose regimens: 375 mg/m2/150 mg/m dose, compared to the 290 mg/m2/115 mg/m2 dose, plus background therapy of at least two nonprotease inhibitor antiretroviral medicinal products, optimized using baseline genotypic resistance testing. 
Morali su imati početnu vrijednost HIV-1 RNA najmanje 1500 kopija/ml, stratificirani su po dobi (od 2 do < 6 godina, od 6 do < 12 godina, te od 12 do 18 godina) i randomizirani na jedan od dvaju režima tipranavira s ritonavirom: doza od 375 mg/m2/150 mg/m2 ili 290 mg/m2/115 mg/m2, plus osnovna terapija s najmanje dva neproteazna antiretrovirusna lijeka, koji su bili optimizirani pomoću početnog testiranja genotipske rezistencije.
Co-administration of protease inhibitors with rifampicin substantially decreases protease inhibitor concentrations. 
Istodobna primjena inhibitora proteaze s rifampicinom znatno smanjuje koncentracije inhibitora proteaze.
P-gp activity is significantly inhibited after the first dose, but there was a slight induction at steady state. 
Aktivnost P-gpa je značajno inhibirana nakon prve doze, ali je u stanju dinamičke ravnoteže uočena blaga indukcija.
low dose ritonavir (this helps Aptivus to reach a high enough level in your blood) other HIV medicines. 
niskom dozom ritonavira (koji pomaže Aptivusu u postizanju dovoljno visokih vrijednosti u krvi) drugim HIV lijekovima.
Your child's doctor will take a blood sample to test how well your child's liver is working (your child's liver function). 
Djetetov liječnik će uputiti uzorke krvi Vašeg djeteta na testiranje koliko dobro funkcionira njegova jetra (jetrena funkcija).
If the coadministration is judged unavoidable, this should be done under close clinical monitoring. 
Ako se istodobna primjena ocijeni nužnom, potrebno je pažljivo kliničko praćenje.
Additional side effects in children and adolescents The most common side effects were generally similar to those described in adults. 
Najčešće nuspojave su općenito bile slične pojavama opisanima za odrasle osobe.
Dosing with Aptivus capsules 500 mg twice daily concomitant with 200 mg ritonavir twice daily for 2 to 4 weeks and without meal restriction produced a mean tipranavir peak plasma concentration (Cmax) of 94.8 ± 22.8 µM for female patients (n=14) and 77.6 ± 16.6 µM for male patients (n=106), occurring approximately 3 hours after administration. 
Doziranje Aptivus kapsula 500 mg dvaput dnevno istodobno s 200 mg ritonavira, u trajanju 2 do 4 tjedana i bez ograničenja u obrocima hrane, rezultiralo je prosječnom vršnom koncentracijom tipranavira u plazmi (Cmax) od 94,8 ± 22,8 µM za ženske bolesnike (n=14) i 77,6 ± 16,6 µM za muške bolesnike (n=106), s Tmax oko 3 sata.
In rats, co-administration with vitamin E increased the bleeding effects of tipranavir (see section 5.3). 
U štakora je istodobna primjena vitamina E povećala učinke tipranavira na krvarenje (vidjeti dio 5.3).
Tipranavir, co-administered with low dose ritonavir, is expected to decrease meperidine concentrations and increase normeperidine metabolite concentrations. 
Očekuje se da tipranavir s niskom dozom ritonavira smanjuje koncentracije meperidina i povećava koncentracije metabolita normeperidina.
Aptivus co-administered with low dose ritonavir, has been associated with reports of significant liver toxicity. 
Primjena Aptivusa s niskom dozom ritonavira povezuje se s prijavama značajne toksičnosti za jetru.
The safety and efficacy of Aptivus in children under 2 years of age has not been established. 
Sigurnost i djelotvornost Aptivusa u djece u dobi ispod 2 godine nisu ustanovljene.
If you notice any symptoms of infection (for example fever, enlarged lymph nodes), please inform your doctor immediately. 
Ako primijetite simptome infekcije (na primjer vrućica, povećani limfni čvorovi), odmah se obratite svom liječniku.
Interaction table 
Tablica s interakcijama
Co-administration of Aptivus and low dose ritonavir with agents primarily metabolised by CYP3A may result in changed plasma concentrations of tipranavir or the other agents, which could alter their therapeutic and undesirable effects (see list and details of considered agents, below). 
Istodobna primjena Aptivusa i niske doze ritonavira s lijekovima koji se prvenstveno metaboliziraju putem CYP3A može rezultirati promijenjenim koncentracijama tipranavira ili drugih lijekova u plazmi, što može promijeniti njihove terapijske i neželjene učinke (vidjeti popis relevantnih lijekova u nastavku).
3, respectively, (ranges 1-1893 and 1 
3 (raspon 1-1893), a u kontrolnoj 166
If you miss a dose of Aptivus and/or ritonavir by less than 5 hours, take your missed dose immediately. 
Ako propustite dozu Aptivusa i/ili ritonavira za manje od 5 sati, odmah uzmite propuštenu dozu.
If you have any further questions about ritonavir or the other medicines your child is prescribed, please ask your child's doctor or pharmacist. 
Ako imate dodatnih pitanja o ritonaviru ili drugim lijekovima koji su propisani Vašem djetetu, obratite se djetetovom liječniku ili ljekarniku.
The in vivo net effect of tipranavir with ritonavir on CYP 1A2, CYP 2C9 and CYP 2C19, indicates, through a preliminary study, an inducing potential of tipranavir with ritonavir on CYP1A2 and, to a lesser extent, on CYP2C9 and P-gp after several days of treatment. 
Preliminarno ispitivanje pokazuje da in vivo neto-učinak tipranavira s ritonavirom na CYP 1A2, CYP 2C9 i CYP 2C19 ukazuje na inducirajući potencijal tipranavira s ritonavirom na CYP1A2 te, u manjoj mjeri, na CYP2C9 i P-gp nakon nekoliko dana liječenja.
In use storage: 60 days (below 25°C) after first opening of the bottle. 
Čuvanje tijekom primjene: 60 dana (ispod 25°C) nakon prvog otvaranja boce.
Most frequently reported moderate or severe adverse reactions in paediatric patients age 2 to < 12 years (reported in 2 or more children, Trial 1182.14, 48 weeks analyses, Full Analysis Set). 
Najčešće umjerene ili teške nuspojave u pedijatrijskoj populaciji u dobi od 2 do <12 godina (prijavljeno za 2 ili više djece, Ispitivanje 1182.14, analize 48 tjedana, svi ispitanici).
R-methadone Cmax ↓ 46% R-methadone AUC ↓ 48% 
R-metadon Cmax ↓ 46% R-metadon AUC ↓ 48%
Colchicine is a substrate of CYP3A4 and P-gp (an intestinal efflux transporter). 
Kolhicin je supstrat CYP3A4 i P-gp (crijevni efluksni prijenosnik).
After 48 weeks of follow-up, the frequency of Grade 3 or 4 ALAT and/or ASAT abnormalities was higher in tipranavir with ritonavir patients compared with comparator arm patients (10% and 3.4%, respectively). 
Nakon 48 tjedana praćenja, učestalost povišenja ALT i/ili AST 3. ili 4. stupnja bila je viša u bolesnika koji su dobivali kombinaciju tipranavira s ritonavirom u usporedbi s bolesnicima u kontrolnoj skupini (10% naspram 3,4%).
Didanosine Cmax ↓ 24% Didanosine AUC ↔ 
Didanozin Cmax ↓ 24% Didanozin AUC ↔
Uncommon: may affect up to 1 in 100 people - Reduction in red and white blood cells - Reduction in blood platelets - Allergic (hypersensitivity) reactions - Decreased appetite - Diabetes - Increased blood sugar - Increased blood levels of cholesterol - Sleeplessness and other sleep disorders 
Manje često: mogu se javiti u do 1 na 100 osoba - smanjenje broja crvenih i bijelih krvnih stanica - smanjenje trombocita - alergijske reakcije (preosjetljivosti) - smanjeni apetit - dijabetes - povišeni šećer u krvi - povišene vrijednosti kolesterola u krvi - nesanica i drugi poremećaji spavanja
C-tipranavir to subjects (n = 8) that received 500 mg tipranavir with 200 mg ritonavir twice daily dosed to steady-state demonstrated that most radioactivity (median 82.3%) was excreted in faeces, while only a median of 4.4% of the radioactive dose administered was recovered in urine. 
C-tipranavira ispitanicima (n = 8) koji su primali 500 mg tipranavira s 200 mg ritonavira dvaput dnevno, dozirano do stanja ravnoteže, pokazala je da se većina radioaktivnosti (prosjek 82,3%) izlučuje stolicom, dok je prosječno samo 4,4% primijenjene radioaktivne doze nađeno u urinu.
Oral contraceptives / Oestrogens Ethinyl oestradiol 0.035 mg / Norethindrone 1.0 mg QD (TPV/r 750/200 mg BID) 
Oralni kontraceptivi / estrogeni Etinilestradiol 0,035 mg / Noretindron 1,0 mg QD (TPV/r 750/200 mg BID)
Aptivus is available as soft capsules for adults and adolescents from 12 years of age (please refer to the respective SmPC for further details). 
Aptivus je dostupan u obliku mekih kapsula za odrasle osobe i adolescente od 12 godina starosti (vidjeti Sažetak opisa svojstava lijeka za Aptivus kapsule).
If the co-administration is nevertheless considered necessary, a close monitoring of the safety of tipranavir and a monitoring of plasma concentrations of atazanavir are strongly encouraged (see section 
Ako se istodobna primjena ipak smatra potrebnom, valja pomno pratiti sigurnost tipranavira i koncentracije atazanavira u plazmi (vidjeti dio 4.4).
In deciding to initiate treatment with Aptivus, co-administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. 
Prilikom odluke o početku liječenja Aptivusom uz istodobnu primjenu niske doze ritonavira, potrebno je pažljivo razmotriti povijest liječenja pojedinog bolesnika te obrasce mutacija povezanih s različitim lijekovima.
Since the renal clearance of tipranavir is negligible, increased plasma concentrations are not expected in patients with renal impairment. 
S obzirom da je bubrežni klirens tipranavira neznatan, ne očekuju se povišene koncentracije u plazmi u bolesnika s oštećenjem bubrega.
- sildenafil, vardenafil, tadalafil (medicines used to produce and maintain an erection). 
Oni mogu smanjiti učinkovitost Aptivusa. - sildenafil, vardenafil, tadalafil (lijekovi koji se primjenjuju za stvaranje i održavanje erekcije).
This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves. 
Tijekom terapije HIV-a može doći do povećanja tjelesne težine i razine lipida i glukoze u krvi, što je djelomično povezano s obnovljenim zdravstvenim stanjem i stilom života, a u slučaju lipida u krvi ponekad i sa samim lijekovima za HIV.
Immunosupressants Cyclosporin Tacrolimus Sirolimus 
Imunosupresivi Ciklosporin
Aptivus, co-administered with low dose ritonavir, when combined with warfarin may be associated with changes in INR (International Normalised Ratio) values, and may affect anticoagulation (thrombogenic effect) or increase the risk of bleeding. 
Kad se Aptivus s niskom dozom ritonavira kombinira s varfarinom, može biti povezan s promjenama vrijednosti INR (international normalized ratio) te može smanjiti antikoagulantni učinak ili povećati rizik krvarenja.
Fatal and non-fatal intracranial haemorrhages (ICH) have been reported in patients receiving Aptivus, many of whom had other medical conditions or were receiving concomitant medicinal products that may have caused or contributed to these events. 
Fatalna i nefatalna intrakranijalna krvarenja (intracranial hemorrhage, ICH) prijavljena su u bolesnika koji su dobivali Aptivus, od kojih su mnogi imali druga medicinska stanja ili su istodobno dobivali lijekove koji su mogli izazvati ili doprinijeti ovim događajima.
Steady-state tipranavir/r: Midazolam Cmax ↓ 13% Midazolam AUC ↑ 181% 
Tipranavir/r u stanju ravnoteže: Midazolam Cmax ↓ 13% Midazolam AUC ↑ 181%
This will depend on, for example: which other medicines you have already taken for HIV which medicines your HIV is resistant to. 
Liječnik će, u suradnji s Vama, odlučiti koje druge lijekove trebate uzimati, što će ovisiti, na primjer: o tome koje ste druge lijekove već uzimali protiv HIV-a o tome na koje lijekove je Vaš HIV otporan.
Each capsule contains 250 mg tipranavir. 
Svaka kapsula sadrži 250 mg tipranavira.
Tipranavir is metabolised by the hepatic system. 
Tipranavir se metabolizira putem jetrenih enzima.
Gastrointestinal disorders very common diarrhoea, nausea common vomiting, flatulence, abdominal pain, abdominal distension, dyspepsia uncommon gastrooesophageal reflux disease, pancreatitis rare lipase increased 
Poremećaji probavnog sustava vrlo često proljev, mučnina često povraćanje, nadutost, bol u abdomenu, distenzija abdomena, dispepsija manje često gastroezofagealna refluksna bolest, pankreatitis rijetko povišena lipaza
In an open-label, dose-finding study of tipranavir plus ritonavir (Trial 1182.14), 28 children who were 12 years of age or above received Aptivus capsules. 
U otvorenom ispitivanju određivanja doze tipranavira s ritonavirom (ispitivanje 1182.14), 28 djece u dobi 12-18 godina dobivalo je Aptivus kapsule.
Therefore, Aptivus should be used with caution, and with increased monitoring frequency, in patients with mild hepatic impairment (ChildPugh Class A). 
Stoga se Aptivus primjenjuje s oprezom, i uz učestalije praćenje, u bolesnika s blagim oštećenjem jetre (Child-Pugh stadij A).
The interaction profile of tipranavir, co-administered with low dose ritonavir, is complex. 
Profil interakcija tipranavira s niskom dozom ritonavira je složen.
Clinical data on fertility are not available for tipranavir. 
Nisu dostupni klinički podaci o tipranaviru s obzirom na plodnost.
Taking Aptivus with etravirine is not recommended. 
Ne preporučuje se uzimanje Aptivusa s etravirinom.
Ethinyl oestradiol Cmax ↓ 52% Ethinyl oestradiol AUC ↓ 43% Mechanism unknown Norethindrone Cmax ↔ Norethindrone AUC ↑ 27% Tipranavir ↔ 
Etinilestradiol Cmax ↓ 52% Etinilestradiol AUC ↓ 43% Mehanizam nepoznat Noretindron Cmax ↔ Noretindron AUC ↑ 27% Tipranavir ↔
Virological response to tipranavir with ritonavir therapy has been evaluated using a tipranavirassociated mutation score based on baseline genotype in RESIST-1 and RESIST-2 patients. 
Virološka reakcija na tipranavir s ritonavirom ocijenjena je i u odnosu na „mutacijski skor“ temeljen na početnoj genotipizaciji bolesnika uključenih u RESIST-1 i RESIST-2.
After baseline and placebo adjustment, the maximum mean QTcF change was 3.2 ms (1-sided 95% Upper CI: 5.6 ms) for the 500/200 mg dose and 8.3 ms (1-sided 95% Upper CI: 10.8 ms) for the supra-therapeutic 750/200 mg dose. 
Uz korekciju za bazalne vrijednosti i vrijednosti nakon izlaganja placebu, maksimalna prosječna QTcF promjena iznosila je 3,2 ms (gornja granica 95% CI: 5,6 ms) za dozu od 500/200 mg, te 8,3 ms (gornja granica 95% CI: 10,8 ms) za supraterapijsku dozu od 750/200 mg.
The baseline characteristics and the key efficacy results at 48 weeks for the paediatric patients receiving Aptivus capsules are displayed in the tables below. 
Početna svojstva i ključni rezultati djelotvornosti tijekom 48 tjedana za djecu liječenu Aptivus kapsulama prikazani su tablično u nastavku teksta.
Aptivus 100 mg/ml oral solution tipranavir 
Aptivus 100 mg/ml oralna otopina tipranavir
Increased ALAT/ASAT monitoring should be considered in these patients. 
Potrebno je razmotriti pojačano praćenje vrijednosti ALT/AST u spomenutih bolesnika.
If indicated, elimination of unabsorbed tipranavir should be achieved by emesis or gastric lavage. 
Ako je indicirano, potrebno je eliminirati neapsorbirani tipranavir indukcijom povraćanja ili ispiranjem želuca.
The mechanism of action is thought to be induction of glucuronosyltransferase by tipranavir/r. 
Smatra se da je mehanizam interakcije indukcija glukuronoziltransferaze djelovanjem tipranavira/r.
It blocks an enzyme called protease that is involved in the reproduction of HIV. 
Inhibira enzim koji se naziva proteaza, a koji je uključen u umnožavanje HIV-a.
First-dose tipranavir/r: 
Prva doza tipranavira/r:
Other HMG-CoA reductase inhibitors should be considered such as pravastatin, fluvastatin or rosuvastatin (see section 4.5). 
Potrebno je razmotriti primjenu drugih inhibitora HMG-CoA reduktaze, kao što su pravastatin, fluvastatin, ili rosuvastatin (vidjeti dio 4.5).
Protease inhibitors (PIs) 
Inhibitori proteaze (IP)
In addition to the opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection. 
Uz oportunističke infekcije, nakon početka uzimanja lijeka za liječenje infekcije HIV-om također može doći i do autoimunih poremećaja (stanje koje se javlja kada imunološki sustav napada zdravo tkivo u tijelu).
No dosing adjustment is required in patients with mild hepatic impairment but patients should be closely monitored (see sections 4.2 and 
Nije potrebno podešavanje doza za bolesnike s blagim oštećenjem jetre, ali se bolesnici moraju pažljivo pratiti (vidjeti dijelove 4.2 i 4.4).
QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of oral solution contains 100 mg tipranavir. 
KVALITATIVNI I KVANTITAVNI SASTAV Jedan ml oralne otopine sadrži 100 mg tipranavira.
Systemic corticosteroid effects including Cushing's syndrome and adrenal suppression have been reported in patients receiving ritonavir and inhaled or intranasally administered fluticasone propionate; this could also occur with other corticosteroids metabolised via the P450 3A pathway e.g. budesonide. 
Sistemski učinci kortikosteroida, uključujući Cushingov sindrom i adrenalnu supresiju prijavljeni su u bolesnika na ritonaviru i na inhalacijskom ili intranazalnom flutikazonpropionatu, što se također može pojaviti uz druge kortikosteroide koji se metaboliziraju putem P450 3A, npr. budezonid.
Amongst the most common adverse reactions reported for Aptivus were gastrointestinal complaints such as diarrhoea and nausea as well as hyperlipidaemia. 
Među najčešće prijavljenim nuspojavama za Aptivus su gastrointestinalne tegobe, kao što su proljev i mučnina, te hiperlipidemija.
C-tipranavir human study (500 mg 
tipranavirom u ljudi (500 mg
Patients with moderate or severe (Child-Pugh B or C) hepatic impairment. 
Bolesnici s umjerenim ili teškim (Child-Pugh B ili C) oštećenjem jetre.
Blood and lymphatic system disorders uncommon neutropenia, anaemia, thrombocytopenia 
Poremećaji krvi i limfnog sustava manje često neutropenija, anemija, trombocitopenija
s r.o. 
S.C.S.
Most frequently reported moderate or severe adverse reactions in paediatric patients aged 12 to 18 years who took Aptivus capsules (reported in 2 or more children, Trial 1182.14, week 48 analyses, Full Analysis Set). 
Najčešće prijavljene umjerene ili teške nuspojave u pedijatrijskoj populaciji starosti 12-18 godina liječene Aptivus kapsulama (prijavljeno za 2 ili više djece, ispitivanje 1182.14, analiza 48 tjedana, svi ispitanici).
If you use oral contraceptives or HRT you have an increased chance of developing a skin rash while taking Aptivus. 
Ako primjenjujete oralne kontraceptive ili HNT, pod povećanim ste rizikom od razvoja osipa na koži tijekom primjene Aptivusa.
If another cause is identified (e.g. acute hepatitis A, B or C virus, gallbladder disease, other medicinal products), then rechallenge with Aptivus may be considered when ASAT/ALAT have returned to the patient's baseline levels. 
Ako se prepozna drugi uzrok (npr. akutni hepatitis A, B ili C, bolest žučnog mjehura, drugi lijekovi), ponovno uvođenje Aptivusa se može razmatrati kada se vrijednosti AST/ALT vrate na početne vrijednosti (prije započinjanja liječenja).
Nevirapine No interaction study performed 
Nevirapin Ne postoje studije interakcija
You should talk to your doctor as you may need to temporarily stop taking either Aptivus or your oral contraceptives or HRT - carbamazepine, phenobarbital and phenytoin (used to treat epilepsy). 
Potrebno je posavjetovati se s liječnikom jer ćete možda trebati privremeno prekinuti s primjenom ili Aptivusa ili oralnih kontraceptiva ili HNT-a - karbamazepin, fenobarbital i fenitoin (primjenjuju se u liječenju epilepsije).
Co-administration of Aptivus with low dose ritonavir, with active substances that are highly dependent on CYP3A for clearance, and for which elevated plasma concentrations are associated with serious and/or life-threatening events. 
Istodobna primjena Aptivusa i niske doze ritonavira s djelatnim tvarima čiji klirens izrazito ovisi o CYP3A, a čije su povišene koncentracije u plazmi povezane s teškim i/ili po život opasnim događajima.
If your child misses a dose of Aptivus and/or ritonavir by less than 5 hours, give the missed dose immediately. 
Ako Vaše dijete propusti dozu Aptivusa i/ili ritonavira za manje od 5 sati, neka odmah uzme propuštenu dozu.